Literature DB >> 10780273

Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping.

J O Svensson1, L Bertilsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10780273

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  3 in total

1.  Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.

Authors:  Agneta Wennerholm; Anna Nordmark; Maria Pihlsgård; Margarita Mahindi; Leif Bertilsson; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2006-06-17       Impact factor: 2.953

2.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Authors:  P Dalén; M Dahl; K Andersson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

3.  Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Authors:  Karin Hellman; Ewa Roos; Anna Osterlund; Anneli Wahlberg; Lars L Gustafsson; Leif Bertilsson; Sten Fredrikson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.